Xolair 150 MG/ML 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTME
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,969
Award facts
- Contract value 100% obligated
- $20,969.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,969.28 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for XOLAIR 150 mg/ml. This delivery order was issued without a set-aside designation on January 15, 2026, with an ultimate completion date of February 5, 2026. DMS Pharmaceutical Group serves as the sole prime contractor on this award with no identified subcontractors, leveraging its position as a critical supplier within the Department of Defense pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent contract, valued at $499,999,999 and awarded November 13, 2025, positions DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide. The PPV-G GEN V program represents a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement and ensure consistent supply of both routine and specialty medications to Department of Defense medical operations. XOLAIR, a biologic immunosuppressant agent, falls within DMS Pharmaceutical Group's established product portfolio of specialty pharmaceuticals and biologics distributed under this framework.
Quick answers
Who was awarded contract SPE2DR26FBTME?
SPE2DR26FBTME was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FBTME worth?
The government has obligated $20,969 on SPE2DR26FBTME.
Is contract SPE2DR26FBTME an order under another contract?
Yes. SPE2DR26FBTME is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTME competed?
The extent of competition for SPE2DR26FBTME was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award